Anti-GP6 mAb – Research Grade (ACT017) from ProteoGenix; catalogue PX-TA1552; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-GP6 mAb – Research Grade (ACT017): A Potential Therapeutic Target in Thrombosis Research
Anti-GP6 monoclonal antibody (ACT017) is a research-grade antibody designed to target glycoprotein VI (GP6), a key platelet surface receptor involved in thrombus formation. GP6 plays a crucial role in platelet activation and aggregation by mediating collagen-induced signaling in damaged blood vessels. As a result, it has emerged as an important therapeutic target in the treatment of thrombotic disorders, offering a potential alternative to conventional antiplatelet therapies.
ACT017 functions by specifically binding to GP6, effectively inhibiting its interaction with collagen and preventing excessive platelet activation. This selective mechanism reduces thrombus formation without significantly impairing hemostasis, minimizing the risk of severe bleeding—a major limitation of current antithrombotic drugs. Research suggests that targeting GP6 with monoclonal antibodies like ACT017 may provide a safer and more effective strategy for managing conditions such as stroke, myocardial infarction, and venous thromboembolism.
As a research-grade antibody, ACT017 is widely used in preclinical studies to investigate GP6’s role in thrombosis and explore novel therapeutic approaches. Its specificity and high binding affinity make it an essential tool for studying platelet function, signaling pathways, and the development of innovative antithrombotic agents. This antibody’s sequence is highly similar to glenzocimab sequence.
By targeting a key player in platelet activation, ACT017 highlights the potential of monoclonal antibodies in advancing thrombosis research and developing next-generation treatments.
ProteoGenix catalogue number PX-TA1552. For research use only.
Target: GP6 mAb – Research Grade (ACT017); Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| GP6 mAb – Research Grade (ACT017) |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
